This is a working overview of lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-04. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
US legislators expressed similar concerns, and bipartisan investigations were launched by the Senate and the House Armed Services Committees. On 17 December, the Senate passed the National Defense Authorization Act for Fiscal Year 2026 with a bipartisan amendment that, if passed by the House, would require Hegseth to provide unedited footage of the strikes and their authorizing orders to both committees or lose part of his travel budget.
Over the years, multiple synthesizers have been developed to assist with automated synthesis, including the Chemspeed Accelerator (SLT106, SLT II, ASW2000, SwingSLT, Autoplant A100, and SLT100), the Symyx system, and Freeslate ScPPR. Recently, researchers have investigated the optimization of these methods for controlled/living radical polymerization (CLRP), which faces issues with oxygen intolerance. This research has led to the development of oxygen-tolerant CLRP, including with the use of enzyme degassing of RAFT (Enz-RAFT), atom-transfer radical (ATRP) that possesses tolerance to air, and photoinduced electron/energy transfer–RAFT (PET–RAFT) polymerization. Through the use of liquid-handling robots, Tamasi et al. demonstrated the use of automated synthesis with executing multi-step procedures, enabling the reactions to investigate more elaborate schemes, such as with scale and complexity. Lee Cronin and his team have developed a modular synthesis machine called the chemputer which uses a dedicated programming language for chemical synthesis.
The egg case genera Palaeoxyris and Fayolia, which are thought to have been produced by hybodonts and xenacanths respectively, two groups of extinct shark-like cartilaginous fish more closely related to modern sharks and rays than to chimaeras, resemble those of bulldog sharks in having a spiral collarettes running around them. Both Palaeoxyris and Fayolia taper towards their ends (with the tapering being more pronounced in Palaeoxyris), with one end having a tendril. Unlike modern sharks, these eggs are typically found in freshwater environments.
==== Retinoids ==== Retinoids, a class of natural and synthetic vitamin A analogues, are widely utilized for their anti-aging effects, specifically in the reduction of facial wrinkles and fine lines. Tretinoin (Retin-A) and tazarotene (Tazorac) are the only topical retinoids approved as medical agents for the treatment of wrinkles and fine lines from photodamage. Other retinoids, such as retinol, retinaldehyde, and retinyl palmitate, are commonly found in over-the-counter cosmeceuticals and have some evidence for reducing wrinkles and fine lines but are regulated as cosmetics rather than medicines. Retinoids function by binding to retinoic acid receptors (RAR) and retinoid-X receptors (RXR), which promotes keratinocyte proliferation, increases epithelial cell turnover, stimulates collagen synthesis, and inhibits collagen degradation. Retinoids also appear to improve the epidermal barrier and reduce transepithelial water loss.
Sources: en.wikipedia.org
== Problems faced in drug delivery == Other problems persist besides just simply getting through the blood–brain barrier. The first of these is that a lot of times, even if a compound transverses the barrier, it does not do it in a way that the drug is in a therapeutically relevant concentration. This can have many causes, the most simple being that the way the drug was produced only allows a small amount to pass through the barrier. Another cause of this would be the binding to other proteins in the body rendering the drug ineffective to either be therapeutically active or able to pass through the barrier with the adhered protein. Another problem that must be accounted for is the presence of enzymes in the brain tissue that could render the drug inactive. The drug may be able to pass through the membrane fine, but will be deconstructed once it is inside the brain tissue rendering it useless. All of these are problems that must be addressed and accounted for in trying to deliver effective drug solutions to the brain tissue.
=== Substrate specificity === Octopine dehydrogenase has at least two structural characteristics that contribute to substrate specificity. Upon binding to NADH, amino acid residues lining either side of the active site within the space between the domains of OcDH act as a "molecular ruler", physically limiting the size of the substrates that can fit into the active site. There is also a negatively charged pocket in the cleft between the two domains that acts an "electrostatic sink" that captures the positively charged side-chain of L-arginine.
News spread quickly of the new discovery, which was correctly seen as an entirely novel physical effect with great scientific—and potentially practical—possibilities. Meitner's and Frisch's interpretation of the discovery of Hahn and Strassmann crossed the Atlantic Ocean with Niels Bohr, who was to lecture at Princeton University. I.I. Rabi and Willis Lamb, two Columbia University physicists working at Princeton, heard the news and carried it back to Columbia. Rabi said he told Enrico Fermi; Fermi gave credit to Lamb. Bohr soon thereafter went from Princeton to Columbia to see Fermi. Not finding Fermi in his office, Bohr went down to the cyclotron area and found Herbert L. Anderson. Bohr grabbed him by the shoulder and said: "Young man, let me explain to you about something new and exciting in physics." It was clear to a number of scientists at Columbia that they should try to detect the energy released in the nuclear fission of uranium from neutron bombardment. On 25 January 1939, a Columbia University team conducted the first nuclear fission experiment in the United States, which was done in the basement of Pupin Hall. The experiment involved placing uranium oxide inside of an ionization chamber and irradiating it with neutrons, and measuring the energy thus released. The results confirmed that fission was occurring and hinted strongly that it was the isotope uranium 235 in particular that was fissioning. The next day, the fifth Washington Conference on Theoretical Physics began in Washington, D.C.
KDEL receptors initiate the mechanism by which proteins are transported from the Golgi to the ER. These proteins were originally from the ER and they escaped into the cis-Golgi. The KDEL signal sequence is recognized by KDEL receptors, which are commonly located in the cis-Golgi, lysosomes, and secretory vesicles. These receptors are recycled during each transport cycle. KDEL receptor binding is dependent on pH, in which the ligand (target protein) binds strongly to the receptor in the cis-Golgi due to the unique low pH (6, in in vitro experiments pH 5 shows strongest binding) characteristic of the biochemical environment of the cis-Golgi network. As the vesicle that contains the KDEL receptor reaches the ER, the receptor is inactive due to the high pH (7.2-7.4) of the ER, resulting in the release of the target protein/ligand. A study conducted by Becker et al. demonstrated through experimentation and simulation that KDEL receptors/cargo clustering at the cell surface is caused by the transport of cargo-synchronized receptors from and to the plasma membrane. The video on the right demonstrates an experiment conducted by Becker et al. demonstrating the dynamics of the KDEL receptor clustering's time dependence with a full experiment from start to finish (60 minutes). Within the paper, the authors note the importance of understanding the mechanism of action of the receptor clustering and dynamic reorganization because of its potential understanding to use for designing targeted therapeutics.
=== Erections === Erections during sleep or when waking up are medically known as nocturnal penile tumescence and colloquially referred to as morning wood. The penis can regularly get erect during sleep and men or males often wake up with an erection. Once a male reaches his teenage years, erections occur much more frequently due to puberty. Erections can occur spontaneously at any time of day, and if clothed may cause a bulge or "hump". This can be disguised or hidden by wearing close-fitting underwear, a long shirt and baggier clothes. Erections are common for male prepubescent children and infants, and can even occur before birth. Spontaneous erections, also known as involuntary or unwanted erections, are normal. Such erections can be embarrassing if they happen in public, such as a classroom or living room.
Sources: en.wikipedia.org
The origin and first recorded use of the term megacap (or any of its various spellings), in relation to stock capitalization, is unclear. It dates back to at least 1997, if not earlier. The S&P 100 was launched on June 15, 1983. The Russell Top 200 Index was launched on September 1, 1992. The Fidelity Mega Cap Stock Fund's inception was on December 28, 1998. The Russell Top 50 Mega Cap Index was launched on January 1, 2005. Also in 2005, investment advisory executive Richard Imperiale noted that some investors were classifying "the top 10 percent of companies by market cap" into a mega cap segment of the stock market. In 2009, the third edition of Stock Investing For Dummies defined mega caps (and ultra caps) as companies with market caps over $50 billion. Subsequent editions used that definition until 2020, when the sixth edition redefined them as having market caps over $200 billion. The 2023 version, retitled Investing in Stocks For Dummies, used the same definition as the sixth edition. The Morningstar US Mega Cap Index was established on March 31, 2011. In 2011, Investing Demystified defined mega-caps as companies with market caps of at least $25 billion, whereas in the same year, The Complete Idiot's Guide to Stock Investing defined them as having market caps at least $50 billion. That's equivalent to $34 billion and $69 billion, respectively, in 2024 using GDP deflator adjustment. In 2014, Asset Allocation Demystified stated that a typical mega cap company had a market cap of over $50 billion. The S&P 500 Top 50 Index was launched on November 30, 2015.
Like DavePhos and JohnPhos, MePhos complexes of Pd catalyze the Suzuki-Miyaura coupling. It can also form the active catalyst in the formation of aryl ketones. Variants of this ligand, including t-BuMePhos, are also commercially available.
There are more than 2.6 million cars in Moscow each day. This number has grown in recent years; as a result, traffic jams and insufficient parking space have become major problems. The Moscow Ring Road (MKAD)—along with the Third Transport Ring and the canceled Fourth Transport Ring—is one of only three freeways running within city limits. Several other roadway systems form concentric circles around the city.
=== Shoreline protection === Healthy coral reefs absorb 97 percent of a wave's energy, which buffers shorelines from currents, waves, and storms, helping to prevent loss of life and property damage. Coastlines protected by coral reefs are also more stable in terms of erosion than those without.
The gastrin-releasing peptide receptor (GRPR), now properly known as BB2 is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain. Gastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation and is a potent mitogen for neoplastic tissues. The effects of GRP are mediated through the gastrin-releasing peptide receptor. This receptor is a glycosylated, 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. The receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. An individual with autism and multiple exostoses was found to have a balanced translocation between chromosome 8 and an X chromosome breakpoint located within the gastrin-releasing peptide receptor gene. The transcription factor CREB is a regulator of human GRP-R expression in colon cancer. Activation MOR1D‐GRPR heteromers in the spinal cord mediate the common troublesome opioid-induced itch.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.